Risk‐adapted, response‐based therapies for pediatric Hodgkin lymphoma have resulted in
5‐year survival exceeding 90%. Although high‐dose chemotherapy and autologous …

The treatment of Hodgkin lymphoma (HL) is one of early success. However, disease‐free
survival (DFS) does not reflect latent organ injury and its impact on health status and well …

Background We adopted ABVD chemotherapy with risk-adapted radiation therapy (RT) as
first-line therapy for children, adolescents and young adults with Hodgkin lymphoma (HL) in …

Lymphomas are responsible for approximately 20% to 25% of annual cancer diagnoses in
the adolescent and young adult (AYA) population. In 2006, the National Cancer Institute and …

Abstract Children's Oncology Group (COG) trial AHOD0431 reduced systemic therapy and
used response-adapted involved-field radiotherapy (IFRT) in early-stage pediatric classic …

Purpose Anti-Müllerian hormone (AMH) is an indicator of oocyte reserve in healthy females.
The role of AMH testing in oncology remains investigational, although its sensitivity and …

Background and objective The underlying molecular mechanisms of gastric cancer (GC)
have yet not been investigated clearly. In this study, we aimed to identify hub genes involved …

Human endogenous retroviruses (ERV) are an integral part of our genome. Expression of
ERV is usually switched off but reactivation of ERV has been observed in varying human …

Background The aim of this study was to evaluate the use and reliability of the new positron
emission tomography (PET)-based response criteria for interim positron emission …

Background: Hodgkin lymphoma (HL) treatment protocols for children, adolescents and
young adults traditionally differ, but the biological and clinical justification for this remains …